The programme of Epstein–Barr virus (EBV) gene expression that leads to virus-induced growth transformation of resting B lymphocytes is initiated through activation of the BamHI W promoter, Wp. The factors regulating Wp, and the basis of its preferential activity in B cells, remain poorly understood. Previous work has identified a B cell-specific enhancer region which is critical for Wp function and which contains three binding sites for cellular factors. Here we focus on one of these sites and show, using bandshift assays, that it interacts with three members of the CREB/ATF family of cell transcription factors, CREB1, ATF1 and ATFa. A mutation which abrogates the binding of these factors reduces Wp reporter activity specifically in B cell lines, whereas a mutation which converts the site to a consensus CREB-binding sequence maintains wild-type promoter function. Furthermore Wp activity in B cell, but not in non-B cell, lines could be inhibited by cotransfection of expression plasmids expressing dominant negative forms of CREB1 and ATF1. Increasing the basal activity of CREB/ATF proteins in cells by treatment with protein kinase A or protein kinase C agonists led to small increases in Wp activity in B cell lines, but did not restore promoter activity in non-B cell lines up to B cell levels. We conclude that CREB/ATF factors are important activators of Wp in a B cell environment but require additional B cell-specific factors in order to mediate their effects.
Abbot, S. D., Rowe, M., Cadwallader, K., Gordon, J., Ricksten, A., Rymo, L. & Rickinson, A. B. (1990). Epstein–Barr virus nuclear antigen 2 induces expression of the virus-coded latent membrane protein.Journal of Virology64, 2126-2134.
[Google Scholar]
Alfieri, C., Birkenbach, M. & Kieff, E. (1991). Early events in Epstein–Barr virus infection of human B lymphocytes.Virology181, 595-608.[CrossRef][Google Scholar]
Bell, A., Skinner, J., Kirby, K. & Rickinson, A. (1998). Characterization of regulatory sequences at the Epstein–Barr virus BamHI W promoter. Virology252, 149-161.[CrossRef][Google Scholar]
Benbrook, D. M. & Jones, N. C. (1994). Different binding specificities and transactivation of variant CREs by CREB complexes. Nucleic Acids Research22, 1463-1469.[CrossRef][Google Scholar]
Chatton, B., Bocco, J. L., Gaire, M., Hauss, C., Reimund, B., Goetz, J. & Kedinger, C. (1993). Transcriptional activation by the adenovirus large E1A product is mediated by members of the cellular transcription factor ATF family which can directly associate with E1A. Molecular and Cellular Biology13, 561-570.
[Google Scholar]
Chatton, B., Bocco, J. L., Goetz, J., Gaire, M., Lutz, Y. & Kedinger, C. (1994). Jun and Fos heterodimerise with ATFa, a member of the ATF/CREB family, and modulate its transcriptional activity.Oncogene9, 375-385.
[Google Scholar]
De Cesare, D., Fimia, G. M. & Sassone-Corsi, P. (1999). Signalling routes to CREM and CREB: plasticity in transcriptional activation.Trends in Biochemical Sciences24, 281-285.[CrossRef][Google Scholar]
Delmas, V., Molina, C. A., Lalli, E., DeGrot, R., Foulkes, N. S., Masquilier, D. & Sassone-Corsi, P. (1994). Complexity and versatility of the transcriptional responses to cAMP.Reviews of Physiology, Biochemistry and Pharmacology124, 1-28.
[Google Scholar]
Fåhraeus, R., Jansson, A., Ricksten, A., Sjoblom, A. & Rymo, L. (1990). Epstein–Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element.Proceedings of the National Academy of Sciences, USA87, 7390-7394.[CrossRef][Google Scholar]
Fåhraeus, R., Palmqvist, L., Nerdstedt, A., Farzad, S., Rymo, L. & Lain, S. (1994). Response to cAMP levels of the Epstein–Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity.EMBO Journal13, 6041-6051.
[Google Scholar]
Foulkes, N. S., Borrelli, E. & Sassone-Corsi, P. (1991). CREM gene: use of alternative DNA binding domains generates multiple antagonists of cAMP induced transcription.Cell64, 739-749.[CrossRef][Google Scholar]
Gaire, M., Chatton, B. & Kedinger, C. (1990). Isolation and characterisation of two novel closely related ATF cDNA clones from HeLa cells.Nucleic Acids Research18, 3467-3473.[CrossRef][Google Scholar]
Harada, S. & Kieff, E. (1997). Epstein–Barr virus nuclear protein LP stimulates EBNA2 acidic domain mediated transcriptional activation.Journal of Virology71, 6611-6618.
[Google Scholar]
Hurst, H., Totty, N. F. & Jones, N. C. (1991). Identification and functional characterisation of the cellular activating transcription factor 43 (ATF-43) protein.Nucleic Acids Research19, 4601-4609.[CrossRef][Google Scholar]
Jansson, A., Masucci, M. & Rymo, L. (1992). Methylation of discrete sites within the enhancer region regulates the activity of the Epstein–Barr virus W promoter in Burkitt lymphoma lines.Journal of Virology66, 62-69.
[Google Scholar]
Jin, X. W. & Speck, S. H. (1992). Identification of critical cis elements involved in mediating Epstein–Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter.Journal of Virology66, 2846-2852.
[Google Scholar]
Johnson, P. F. & McKnight, S. L. (1989). Eukaryotic transcriptional regulatory proteins.Annual Review of Biochemistry58, 799-839.[CrossRef][Google Scholar]
Kieff, E. (1996). Epstein–Barr virus and its replication. In Fields Virology, pp. 2343-2396. Edited by B. N. Fields, D. M. Knipe & P. M. Howley. Philadelphia: Lippincott–Raven.
Landschulz, W. H., Johnson, P. F. & McKnight, S. L. (1989). The DNA binding domain of the rat liver nuclear protein C/EBP is bipartite.Science243, 1681-1688.[CrossRef][Google Scholar]
Li, Q. X., Young, L. S., Niedobitek, G., Dawson, C., Birkenbach, M., Wang, F. & Rickinson, A. B. (1992). Epstein–Barr virus infection and replication in a human epithelial cell system.Nature356, 347-350.[CrossRef][Google Scholar]
MacCallum, P., Karimi, L. & Nicholson, L. J. (1999). Definition of transcription factors which bind the differentiation responsive element of the Epstein–Barr virus BZLF1 promoter in human epithelial cells.Journal of General Virology80, 1501-1512.
[Google Scholar]
Masson, N., John, J. & Lee, K. A. W. (1993). In vitro phosphorylation studies of a conserved region of the transcription factor ATF1.Nucleic Acids Research21, 4166-4173.[CrossRef][Google Scholar]
Meyer, T. E. & Habener, J. F. (1993). Cyclic adenosine 3′,5′-monophosphate response element binding protein (CREB) and related transcription activating deoxyribonucleic acid binding proteins.Endocrine Reviews14, 269-290.
[Google Scholar]
Montminy, M. R., Sevarino, K. A., Wagner, J. A., Mandel, G. & Goodman, R. H. (1986). Identification of a cyclic AMP responsive element within the rat somatostatin gene.Proceedings of the National Academy of Sciences, USA83, 6682-6686.[CrossRef][Google Scholar]
Nilsson, T., Sjoblom, A., Masucci, M. G. & Rymo, L. (1993). Viral and cellular factors influence the activity of the Epstein–Barr virus BCR2 and BWR1 promoters in cells of different phenotype.Virology193, 774-785.[CrossRef][Google Scholar]
Nitsche, F., Bell, A. & Rickinson, A. (1997). Epstein–Barr virus leader protein (EBNA-LP) enhances the EBNA2-mediated transactivation of latent membrane protein LMP1 expression: a role for the W1W2 repeat domain. Journal of Virology71, 6619-6628.
[Google Scholar]
Puglielli, M. T., Woisetschlaeger, M. & Speck, S. H. (1996). oriP is essential for EBNA gene promoter activity in Epstein–Barr virus immortalized lymphoblastoid cell lines.Journal of Virology70, 5758-5768.
[Google Scholar]
Rehfuss, R. P., Walton, K. M., Loriaux, M. M. & Goodman, R. H. (1991). The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A.Journal of Biological Chemistry266, 18431-18434.
[Google Scholar]
Rickinson, A. B. & Kieff, E. (1996). Epstein–Barr virus. In Fields Virology, pp. 2397-2446. Edited by B. N. Fields, D. M. Knipe & P. M. Howley. Philadelphia: Lippincott–Raven.
Ricksten, A., Olsson, A., Andersson, T. & Rymo, L. (1988). The 5′ flanking region of the gene for the Epstein–Barr virus-encoded nuclear antigen 2 contains a cell type specific cis-acting regulatory element that activates transcription in transfected B cells.Nucleic Acids Research16, 8391-8410.[CrossRef][Google Scholar]
Rooney, C. M., Brimmell, M., Buschle, M., Allan, G., Farrell, P. J. & Kolman, J. L. (1992). Host cell and EBNA2 regulation of Epstein–Barr virus latent cycle promoter activity in B lymphocytes.Journal of Virology66, 496-504.
[Google Scholar]
Sample, J., Hummel., M., Braun, D., Birkenbach, M. & Kieff, E. (1986). Nucleotide sequences of mRNAs encoding Epstein–Barr virus nuclear proteins: a probable transcriptional initiation site.Proceedings of the National Academy of Sciences, USA83, 5096-5100.[CrossRef][Google Scholar]
Sjöblom, A., Yang, W., Palmqvist, L., Jansson, A. & Rymo, L. (1998). An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein–Barr virus LMP1 gene promoter.Journal of Virology72, 1365-1376.
[Google Scholar]
Sugano, N., Chen, W., Roberts, M. L. & Cooper, N. R. (1997). Epstein–Barr virus binding to CD21 activates the initial viral promoter via NF-KB activation.Journal of Experimental Medicine186, 1-7.[CrossRef][Google Scholar]
Sung, N. S., Kenney, S., Gutsch, D. & Pagano, J. S. (1991). EBNA2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein–Barr virus.Journal of Virology65, 2164-2169.
[Google Scholar]
Walton, K. M., Rehfuss, R. P., Chrivia, J. C., Lochner, J. E. & Goodman, R. H. (1992). A dominant repressor of cyclic adenosine 3′,5′ monophosphate (cAMP)-regulated enhancer binding protein activity inhibits the cAMP mediated induction of the somatostatin promoter in vivo.Molecular Endocrinology6, 647-655.
[Google Scholar]
Wang, F., Tsang, S.-F., Kurilla, M. G., Cohen, J. J. & Kieff, E. (1990). Epstein–Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.Journal of Virology64, 3407-3416.
[Google Scholar]
Wang, J., Huang, J. M. & Montalvo, E. A. (1997). Characterization of proteins binding to the ZII element in the Epstein–Barr virus BZLF1 promoter: transactivation by ATF1.Virology227, 323-330.[CrossRef][Google Scholar]
Wilson, B. E., Mochon, E. & Boxer, L. M. (1996). Induction of bcl-2 expression by phosphorylated CREB proteins during B cell activation and rescue from apoptosis. Molecular and Cellular Biology16, 5546-5556.
[Google Scholar]
Woisetschlaeger, M., Yandava, C. N., Furmanski, L. A., Strominger, J. L. & Speck, S. H. (1990). Promoter switching in Epstein–Barr virus during the initial stages of infection of B lymphocytes. Proceedings of the National Academy of Sciences, USA87, 1725-1729.[CrossRef][Google Scholar]
Woisetschlaeger, M., Jin, X. W., Yandava, C. N., Furmanski, L. A., Strominger, J. L. & Speck, S. H. (1991). Role for the Epstein–Barr virus nuclear antigen 2 in viral promoter switching during the initial stages of infection. Journal of Virology88, 3942-3946.
[Google Scholar]
Xie, H. & Rothstein, T. L. (1995). Protein kinase C mediates activation of nuclear cAMP response element binding protein (CREB) in B lymphocytes stimulated through surface Ig. Journal of Immunology154, 1717-1723.
[Google Scholar]
Xie, H., Wang, Z. & Rothstein, T. L. (1996). Signaling pathways for antigen receptor-mediated induction of transcription factor CREB in B lymphocytes. Cellular Immunology169, 264-270.[CrossRef][Google Scholar]
Yang, Y. M., Dolan, L. R. & Ronai, Z. (1996). Expression of dominant negative CREB reduces resistance to radiation of human melanoma cells. Oncogene12, 2223-2233.
[Google Scholar]
Ying, L., Morris, B. J. & Sigmund, C. D. (1997). Transactivation of the human renin promoter by the cyclic AMP/protein kinase A pathway is mediated by both cAMP responsive element binding protein-1 (CREB)-dependent and CREB-independent mechanisms in Calu-6 cells. Journal of Biological Chemistry272, 2412-2420.[CrossRef][Google Scholar]
Zimber-Strobl, U., Suentzenich, K.-O., Laux, G., Eick, E., Cordier, M., Calender, A., Billaud, M., Lenoir, G. M. & Bornkamm, G. W. (1991). Epstein–Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. Journal of Virology65, 415-423.
[Google Scholar]